MET and glioblastoma: Over the past decade, an increasingly detailed definition of the complex network of interplaying oncogenic pathways contributing to abnormal tumor cell functions has led to the development of different targeted therapies, such as those suppressing kinase activities (e.g., c-Met, PI3K, VEGFR), which unfortunately have generally yielded disappointing results in GBM.